CoChat

Abstract CT074: Non-comparative, open-label, multiple cohort, phase 1/2 study to evaluate nivolumab (NIVO) in patients with virus-associated tumors (CheckMate 358): Efficacy and safety in Merkel cell carcinoma (MCC)

Topalian, Suzanne L., Bhatia, Shailender, Hollebecque, Antoine, Awada, Ahmad, Boer, Jan Paul De, Kudchadkar, Ragini R., Goncalves, Anthony, Delord, Jean-Pierre, Martens, Uwe M., Picazo, Jose Maria Lopez, Oaknin, Ana, Spanos, William C., Aljumaily, Raid, Sharfman, William H., Rao, Shangbang, Soumaoro, Ibrahima, Cao, Alexander, Nghiem, Paul, Schadendorf, Dirk · 2017 · Cancer Research
Cited by 151

The DOI matches its Crossref record.

Abstract

Background: NIVO (anti-PD-1) is approved for the treatment of several cancers including advanced melanoma, but its efficacy in other types of skin cancer has not yet been evaluated. MCC is a rare and aggressive form of skin cancer, with most tumors being associated with the Merkel cell polyomavirus. MCCs frequently express PD-L1, and MCC-reactive T cells express PD-1. Methods: In CheckMate 358 (NCT02488759), patients (pts) with 5 types of advanced virus-associated cancers who had received ≤2 prior therapies, with an ECOG PS of 0-1, were eligible to receive NIVO 240 mg Q2W until progression or unacceptable toxicity. Key exclusion criteria were active brain metastases, autoimmune disease, hepatitis, and HIV infection. Primary endpoints included objective response rate (ORR by RECIST v1.1) and safety; secondary endpoints were duration of response, progression-free survival (PFS), and overall survival (OS). Twenty-five pts with MCC were treated with a median follow-up of 26 wks (range: 5-35). Results: Among 25 treated pts, median age was 66 yrs, 68% were male, and 60% were treatment-naive; 12 of 18 (67%) tested tumors were virus-positive. In 22 response-evaluable pts, ORR was 68% (table) with ongoing responses in 13 of 15 (87%) pts. Responses occurred in treatment-naive pts (71%), in pts with 1-2 prior systemic therapies (63%), and in both virus-positive and virus-negative tumors; 67% of responses occurred at ~8 weeks. At 3 months, PFS and OS rates were 82% and 92%, respectively. Treatment-related adverse events of any grade and grade 3/4 occurred in 68% and 20% of pts; 12% of pts had treatment-related AEs that led to NIVO discontinuation. Response to treatmentResponse-evaluable pts (N=22)Treatment-naive pts (n=14)Pts with 1-2 prior systemic therapies (n=8)Best overall response – n (%)Complete response3 (14)3 (21)0Partial response12 (55)7 (50)5 (63)Stable disease4 (18)3 (21)1 (13)Progressive disease3 (14)1 (7)2 (25)ORR – % (95% CI)68 (45–86)71 (42–92)63 (25–92)Time to response, months; median (range)2.0 (1.8–5.3)––Duration of response, months; median (range)Not reached (0.0–5.6)–– Conclusions: NIVO induces rapid and durable tumor regressions in the majority of treatment-naive and treatment-experienced pts with advanced MCC, with a manageable safety profile. Updated clinical response and biomarker data will be presented. Citation Format: Suzanne L. Topalian, Shailender Bhatia, Antoine Hollebecque, Ahmad Awada, Jan Paul De Boer, Ragini R. Kudchadkar, Anthony Goncalves, Jean-Pierre Delord, Uwe M. Martens, Jose Maria Lopez Picazo, Ana Oaknin, William C. Spanos, Raid Aljumaily, William H. Sharfman, Shangbang Rao, Ibrahima Soumaoro, Alexander Cao, Paul Nghiem, Dirk Schadendorf. Non-comparative, open-label, multiple cohort, phase 1/2 study to evaluate nivolumab (NIVO) in patients with virus-associated tumors (CheckMate 358): Efficacy and safety in Merkel cell carcinoma (MCC) [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2017; 2017 Apr 1-5; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2017;77(13 Suppl):Abstract nr CT074. doi:10.1158/1538-7445.AM2017-CT074

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1538-7445.am2017-ct074

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 151

Metadata

Authors
Topalian, S. L., Bhatia, S., Hollebecque, A., Awada, A., Boer, J. P. D., Kudchadkar, R. R., Goncalves, A., Delord, J.-P., Martens, U. M., Picazo, J. M. L., Oaknin, A., Spanos, W. C., Aljumaily, R., Sharfman, W. H., Rao, S., Soumaoro, I., Cao, A., Nghiem, P., & Schadendorf, D.
Venue
Cancer Research
Published
2017-07-01
Volume
77
Issue
13_Supplement
Pages
CT074-CT074
ISSN
  • 0008-5472 (ISSN-L)
  • 1538-7445
OpenAlex
W2739554663
Cited by
151
References
0
Type
conference abstract
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Abstract CT074: Non-comparative, open-label, multiple cohort, phase 1/2 study to evaluate nivolumab (NIVO) in patients with virus-associated tumors (CheckMate 358): Efficacy and safety in Merkel cell carcinoma (MCC). https://app.cochat.ai/papers/10.1158/1538-7445.am2017-ct074
The paper
Topalian, S. L., Bhatia, S., Hollebecque, A., Awada, A., Boer, J. P. D., Kudchadkar, R. R., Goncalves, A., Delord, J.-P., Martens, U. M., Picazo, J. M. L., Oaknin, A., Spanos, W. C., Aljumaily, R., Sharfman, W. H., Rao, S., Soumaoro, I., Cao, A., Nghiem, P., & Schadendorf, D. (2017). Abstract CT074: Non-comparative, open-label, multiple cohort, phase 1/2 study to evaluate nivolumab (NIVO) in patients with virus-associated tumors (CheckMate 358): Efficacy and safety in Merkel cell carcinoma (MCC). Cancer Research. https://doi.org/10.1158/1538-7445.am2017-ct074

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.